EN DE
Watch Medicon Hellas S.A. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Medicon Hellas S.A. (MEDIC) fair value: what the stock is really worth

As of Nov 5, 2026: fair value (intrinsic value) of Medicon Hellas S.A. stock €9.30, price €3.10, upside +200.0%, quality 49 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare GR · ISIN GRS424003002

MH Medicon Hellas S.A. logo Thin data Nov 5, 2026

Medicon Hellas S.A.

MEDIC · AT
Cheap, value-trap risk

The stock costs 67% less than our calculation considers fair.

Fair value €9.30 · Strongly undervalued
Solidly profitable · 13.2% net margin (TTM)
Ranks above peers (10/13)
Even on cautious assumptions the value is 52% above the price (€4.71).
Quality 49/100
Mixed Growth (revenue 5y +10.3 %/yr in EUR)
Moderate debt
Moderate moat 55/100 · thin data
Thin data
Watch Medicon Hellas S.A. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€4.96 €1.96 Fair Value €9.30 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.

How to read this chart

60‑month range €1.96 – €4.96 · fair‑value band €4.71 – €12.60 · the €3.10 price screens below the €9.30 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.

Follow Medicon Hellas in your weekly email

Every Wednesday you see whether Medicon Hellas is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Medicon Hellas S.A. operates in the diagnostics industry. The company offers instruments, tests, and procedures for public and private hospitals, primary care centers, diagnostic centers, and private laboratories in Greece and internationally.

Show moreShow less

The company distributes various analyzer sysytem for chemistry, immunochemistry and hematology labs, intensive care units, and point-of-care systems.

It also produces reagents for various analyzers, such as specific protein and hematology, as well as clinical chemistry reagents comprising control and calibration materials, and tests.

In addition, the company engages in the production of cosmetic and skin care products under the Miss Beaute brand name. Further, it develops and sells software for laboratory and medical applications, and supplies IT systems to healthcare providers.

Additionally, the company remanufactures and resells chemistry, hematology, blood gas, and immunochemistry analyzers; and provides contract remanufacturing and diagnostics laboratory services. Medicon Hellas S.A. was founded in 1988 and is headquartered in Gerakas, Greece.

Stock analysis

Medicon Hellas S.A. (MEDIC) currently trades at €3.10, while our model-based Fair Value estimate is €9.30, implying the stock looks roughly 67% undervalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of €13.37 per share, and 21 of the 26 models we run sit above the €3.10 price.

Bear case: the Asset-Based group reads lowest at €1.41, and 5 of the 26 models stay below the price. Data coverage for this calculation is low.

Scenario range: €4.71 (bear) to €12.60 (bull), the price of €3.10 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Medicon Hellas S.A. reported revenue of €20.8M in FY2022 versus €13.8M in FY2018, a compound +10.8%/yr. Reported net income was €2.5M in FY2022, compounding +8.5%/yr from FY2018.

Key figures

Market cap €13.7M Micro · P/E ratio 18.1 · P/S ratio 2.21 · EPS (TTM) €0.1710 · Net margin 12.2% · Return on equity 12.4% · Return on assets (EBIT) 9.1% (5-year average) · Operating margin 17.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 55 out of 100 (low confidence).

What moves the price

The share trades about 1% below its 52-week high and 30% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 200%, MEDIC screens cheaper than that median.

Fair Value models

Bear €4.71 Fair Value €9.30 Bull €12.60
Price €3.10 · Upside +200.0%
Capped: our models arrive at a very high value here. We deliberately show a more cautious Fair Value.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF €1.33 €2.44 €4.06 77
Growth DCF €1.32 €2.33 €3.74 76
Owner Earnings €3.25 €5.47 €8.69 75
All 26 models by family
DCF Models
FCF DCF €1.33 €2.44 €4.06 77
Owner Earnings €3.25 €5.47 €8.69 75
5Y Revenue Exit €4.84 €9.56 €15.93 70
5Y EBITDA Exit €7.37 €14.55 €23.42 72
5Y P/E Exit €5.40 €10.66 €16.53 68
10Y Revenue Exit €3.19 €6.95 €12.60 63
10Y EBITDA Exit €4.93 €10.24 €18.14 65
10Y P/E Exit €3.75 €7.68 €13.05 61
Earnings-Based
Graham-Dodd €3.90 €15.50 €21.06 64
Lynch FV €3.84 €5.49 €7.14 61
PEG = 1.0 €3.84 €5.49 €7.14 57
EPV €3.60 €4.18 €4.67 74
Dividend Discount
Gordon GGM €0.1900 €0.3400 €0.4800 67
DDM Multi-Stage €0.1900 €0.3100 €0.3700 67
Multiples
P/E Multiple €9.46 €12.61 €15.76 63
P/S Multiple €7.31 €9.74 €12.18 58
P/B Multiple €12.90 €17.20 €21.51 55
EV/EBIT €10.45 €14.13 €17.82 66
EV/EBITDA €12.38 €16.71 €21.04 67
EV/Revenue €7.28 €10.67 €14.05 53
Asset-Based
NCAV (Graham) €0.9300 €1.41 €1.77 54
Growth DCF
Growth DCF €1.32 €2.33 €3.74 76
Rev-Margin DCF €4.84 €9.39 €14.95 70
Economic Profit
Residual Income €3.63 €4.44 €6.53 75
ROIC Compounder €3.60 €4.43 €5.65 72
Growth Earnings
Growth-Adj P/E €6.97 €9.96 €12.95 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 49/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 60
How much profit the company makes from its sales and capital
Quality Growth 34
Are margins and returns getting better?
Cashflow 29
Do the profits arrive as real cash?
Financial strength 62
Debt, balance sheet and risk of trouble
Investment 63
Does it invest with discipline instead of growing at any price?
Low Volatility 83
How calm the share price moves, does not count
Price momentum 63
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 77
Distance to the 52-week high, does not count
New shares 40
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 64/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−3.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.3%
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.2%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−6.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−6.0%
Dividend (yield on the price)0.0%
Profit margin 2017 to 2022 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.15% → 19%

Watch MEDIC, get fair value alerts →

Compare Medicon Hellas S.A. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks

Beats the industry median on 10/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 49 · Below median
Fair Value upside +200.0% · Top 25%
Profitability
Return on equity (12 months) 12.4% · Above median
Return on assets 8.0% · Above median
Net margin (12 months) 13.2% · Above median
Operating margin (12 months) 17.9% · Above median
Growth and dividend
Revenue growth (quarter YoY) 7.6% · Above median
Dividend yield (12 months) 0.0% · Bottom 25%
Balance sheet
Debt / equity 0.58× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 18.1× · Cheaper than median
P/B 0.90× · Cheapest 25%
P/S (12 months) 0.82× · Cheapest 25%
EV/EBITDA 4.3× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 15
FUTURE (revenue growth)38 · sector 25
PAST (return on equity)50 · sector 29
HEALTH (low debt)71 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.40 $113.53 +43% vs MEDIC
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥50.43 ¥55.21 +9% vs MEDIC
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,860 ₹1,947 +5% vs MEDIC
Haleon plc HLN $9.14 $8.61 −6% vs MEDIC
Merck KGaA MRK €148.75 €109.18 −27% vs MEDIC
Galderma Group GALD CHF 191.75 CHF 109.86 −43% vs MEDIC
Takeda Pharmaceutical Company TAK $21.02 $11.31 −46% vs MEDIC
Teva Pharmaceutical Industries Limited TEVA $42.61 $20.74 −51% vs MEDIC
Sandoz Group SDZ CHF 83.78 CHF 39.70 −53% vs MEDIC
Divi's Laboratories Limited DIVISLAB ₹10,321 ₹1,567 −85% vs MEDIC

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Medicon Hellas S.A.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Medicon Hellas S.A. Fair Value". https://www.fairvalue-calculator.com/stock/MEDIC

Frequently asked questions

Is Medicon Hellas S.A. (MEDIC) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of €9.30 versus a price of €3.10, about +200% upside (undervalued).
What is the fair value of MEDIC?
Our model-based fair value for Medicon Hellas S.A. is €9.30 (as of Nov 5, 2026), built from audited fundamentals. The current price: €3.10.
What is the quality score of MEDIC?
Medicon Hellas S.A. has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Medicon Hellas S.A. (MEDIC)?
Our model-based price target is the fair value of €9.30 (as of Nov 5, 2026) from 26 valuation models. Cautious scenario €4.71, optimistic scenario €12.60. It is a calculation from audited fundamentals, not an analyst target.
What is the Medicon Hellas S.A. stock forecast for 2026?
Our models put fair value at €9.30, about +200% upside versus a price of €3.10 (undervalued). Cautious scenario €4.71, optimistic scenario €12.60. The calculation is refreshed regularly with new filings.
What is the revenue of Medicon Hellas S.A. (MEDIC)?
Medicon Hellas S.A. reported trailing-twelve-month revenue of about €18.6M (latest available figure, as of Nov 5, 2026).
What is the intrinsic value of Medicon Hellas S.A. (MEDIC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medicon Hellas S.A. it is €9.30 per share (as of Nov 5, 2026), against a price of €3.10. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Medicon Hellas S.A. stock overvalued or undervalued in 2026?
As of Nov 5, 2026, MEDIC trades below its calculated fair value: price €3.10, fair value €9.30, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MEDIC?
No. The price is what the market pays today (€3.10); the fair value is what the company's own numbers justify (€9.30). For Medicon Hellas S.A. the two are €6.20 per share apart. That gap is exactly why we show both numbers side by side.
How much is Medicon Hellas S.A. worth?
The market values Medicon Hellas S.A. at about €13.7M (market capitalisation, as of Nov 5, 2026). Per share that is €3.10; our models calculate a fair value of €9.30 per share.
What do the bullish and bearish scenarios say about MEDIC?
Our models span a range for Medicon Hellas S.A.: cautious scenario €4.71, base €9.30, optimistic €12.60 per share (as of Nov 5, 2026, price €3.10). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of MEDIC?
Medicon Hellas S.A. trades at a price-to-earnings ratio of 18.1 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €9.30 is built from several models across several years. Other multiples: P/B 0.9, P/S 0.8, EV/EBITDA 4.3.
How solid is the balance sheet of Medicon Hellas S.A. (MEDIC)?
Balance-sheet figures for Medicon Hellas S.A. (as of Nov 5, 2026): return on equity 12.4%, debt of 0.58 per unit of equity. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is MEDIC from its 52-week high?
Medicon Hellas S.A. trades at €3.10, about 1% below its 52-week high of €3.12 and 30% above the low of €2.39 (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of €9.30 is for.
Which stocks are comparable to Medicon Hellas S.A.?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Medicon Hellas S.A. stock attractive at the current price?
The data as of Nov 5, 2026: price €3.10, calculated fair value €9.30 (+200%), Quality Score 49/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MEDIC calculated?
We run Medicon Hellas S.A. through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of €9.30 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Medicon Hellas S.A. currently trades 67% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Medicon Hellas S.A. (MEDIC)?
The closing price on Nov 5, 2026 was €3.10. Our model-based fair value is €9.30, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Medicon Hellas S.A. right now?
The large discount to fair value meets weak quality (49/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (€4.71). The market is more pessimistic than our downside scenario. The model range is unusually wide (€4.71 to €12.60). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Medicon Hellas S.A.

How large is the market capitalisation of Medicon Hellas S.A. (MEDIC)?
The market capitalisation of Medicon Hellas S.A. is €13.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Medicon Hellas S.A. (MEDIC)?
The price-to-sales ratio of Medicon Hellas S.A. is 2.21 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Medicon Hellas S.A. (MEDIC)?
Earnings per share at Medicon Hellas S.A. are €0.1710 (price ÷ EPS = P/E 18.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Medicon Hellas S.A. (MEDIC)?
The net margin of Medicon Hellas S.A. is 12.2% (fiscal year 2022). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Medicon Hellas S.A. (MEDIC)?
The return on equity (ROE) of Medicon Hellas S.A. is 12.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Medicon Hellas S.A. (MEDIC)?
On an EBIT basis the return on assets of Medicon Hellas S.A. is 9.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Medicon Hellas S.A. (MEDIC)?
The operating margin of Medicon Hellas S.A. is 17.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Medicon Hellas S.A. (MEDIC)?
Revenue at Medicon Hellas S.A. is growing +7.6% versus a year earlier (3y avg +15.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Medicon Hellas S.A. (MEDIC)?
Earnings per share at Medicon Hellas S.A. are growing +92.1% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed

Watch Medicon Hellas S.A. in the live analysis

One click puts Medicon Hellas S.A. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.